NCT05691699View on ClinicalTrials.gov

A Study to Assess Adverse Events and How Single and Multiple Ascending Doses of ABBV-903 Move Through the Body in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

January 3, 2023

Primary Completion Date

October 23, 2023

Study Completion Date

October 23, 2023

Conditions
Healthy Volunteer
Interventions
DRUG

ABBV-903

Capsule; oral

DRUG

Placebo for ABBV-903

Capsule; oral

DRUG

Itraconazole

Capsule; oral

Trial Locations (1)

60030

Acpru /Id# 251279, Grayslake

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY